Insights & news

Grand-Duchy of Luxembourg - Creation of National Medicines Agency

  • 06/01/2020
  • Articles

The Council of Government of the Grand-Duchy of Luxembourg approved on 20 December 2019 a draft bill that provides for the creation of a national medicines agency which will be known as "Agence luxembourgeoise des médicaments et des produits de santé" (« ALMPS ») (see attached press release). As its name suggests, ALMPS will be responsible for a range of products, including pharmaceuticals, medical devices, cosmetics, food supplements and other health products. As a result, Luxembourg will cease to be one of the few European countries without a medicines agency that is separate from the executive branch of government.
 
According to the press release, once operational, ALMPS will be in a better position to cope with a range of public health issues, including health risk management, medicine shortages and universal access to medicines.
 
Additionally and significantly, ALMPS will also be given an economic remit in that it will facilitate and preserve investment in the life sciences sector (the press release expressly mentions the biotechnology industry). ALMPS is supposed to achieve that goal by creating legal certainty in the form of a regulatory framework which will be “precise” and “administered efficiently” and will govern activities such as production, commercialisation and clinical trials.       

 

Attachments:

Key contacts

Related practice areas

Related insights

Sign up for updates
    • 09/07/2020
    • Articles

    Court of Justice of European Union Is Asked Preliminary Questions on Application of Falsified Medicines

    Attached is a note discussing a German reference for a preliminary ruling seeking clarification from the Court of Justice of the European Union regarding the application of the Falsified Medicines Directive to parallel-traded medicines. A judgment is due in 2021.

    Read more
    • 07/07/2020
    • Articles

    European Medicines Agencies Network Strategy to 2025

    The European Medicines Agency (EMA) and the national competent authorities (NCAs) of the 27 EU Member States in addition to those of Iceland, Liechtenstein and Norway presented on 6 July 2020 a proposed network strategy for tackling healthcare challenges in a rapidly evolving environment (see, attachment). The strategy is supposed to apply until 2025 and stakeholders are invited to submit their comments in response to an online questionnaire by 4 September 2020.

    Read more
    • 02/07/2020
    • Articles

    Healthcare Priorities of German Presidency of EU Council

    The German government assumed yesterday for the latter part of 2020 the rotating Presidency of the Council of the European Union. The policy priorities of that Presidency were spelled out in the attached document entitled “Together for Europe’s recovery”. Not surprisingly, healthcare forms a focal point of these priorities in a number of diverging ways:

    Read more

Subscribe to our updates

Please select the practice areas you are interested in: *